- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06561360
털세포백혈병(HCL) 환자를 대상으로 베무라페닙과 오비누투주맙을 클라드리빈 및 리툭시맙과 비교한 연구
이전에 치료받지 않은 털상세포백혈병(HCL) 환자를 대상으로 베무라페닙+오비누투주맙과 클라드리빈+리툭시맙을 비교한 무작위 다기관 제2상 연구
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Jae Park, MD
- 전화번호: 646-608-3743
- 이메일: parkj6@mskcc.org
연구 연락처 백업
- 이름: Mark Geyer, MD
- 전화번호: 646-608-3745
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 아직 모집하지 않음
- Dana Farber Cancer Institute
-
연락하다:
- Eric Winer, MD
- 전화번호: (617) 632-6876
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 아직 모집하지 않음
- Mayo Clinic Cancer Center
-
연락하다:
- Sameer Parikh, M.B.B.S.
- 전화번호: 507-218-0772
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- 모병
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
-
연락하다:
- Jae Park, MD
- 전화번호: 646-608-3743
-
Middletown, New Jersey, 미국, 07748
- 모병
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
연락하다:
- Jae Park, MD
- 전화번호: 646-608-3743
-
Montvale, New Jersey, 미국, 07645
- 모병
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
연락하다:
- Jae Park, MD
- 전화번호: 646-608-3743
-
-
New York
-
Commack, New York, 미국, 11725
- 모병
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
-
연락하다:
- Jae Park, MD
- 전화번호: 646-608-3743
-
Harrison, New York, 미국, 10604
- 모병
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
연락하다:
- Jae Park, MD
- 전화번호: 646-608-3743
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
연락하다:
- Jae Park, MD
- 전화번호: 646-608-3743
-
Uniondale, New York, 미국, 11553
- 모병
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
연락하다:
- Jae Park, MD
- 전화번호: 646-608-3743
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- 모병
- Ohio State University
-
연락하다:
- Seema Bhat, MD
- 전화번호: 614-293-3196
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients must be ≥ 18 years of age
-
Histologically confirmed classical HCL by the enrolling institution
-
Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.
-
Has not received any prior therapy for the disease
-
Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K
-
ECOG performance status of 0 - 2
-
Acceptable pre-study organ function during screening as defined as:
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
- Serum creatinine ≤ 1.5x ULN
-
Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec
-
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab
-
For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
-
Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential
Exclusion Criteria:
-
Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.
-
Known hypersensitivity to any of the study drugs.
-
Patients with known long QT syndrome or uncorrectable electrolyte abnormalities
-
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
-
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.
-
Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)
-
Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.
-
Live vaccination within 28 days of randomization
-
Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
-
Malabsorption syndrome or other condition that precludes enteral route of administration
-
Patients with HCL variant (as defined by absence of expression of CD25)
-
Pregnant or lactating, or intending to become pregnant during the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Vemurafenib plus Obinutuzumab
Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment. |
Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. |
|
활성 비교기: Standard treatment of Cladribine plus Rituximab
Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1. |
Cladribine IV on days 1-5 concurrently with rituximab. Rituximab on days 1-5 concurrently with rituximab. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
incidences of ≥ grade 3 treatment-related toxicities
기간: within 6 months of treatment
|
per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments |
within 6 months of treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
complete remission
기간: 2 years
|
Response will be determined by the Consensus Resolution response criteria. Complete response (CR)
|
2 years
|
|
partial response
기간: 2 years
|
Partial response (PR) °A normalization of cytopenias °≥50% reduction in organomegaly and bone marrow hairy cells. |
2 years
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Jae Park, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 백혈병
- 헴 및 림프병
- 백혈병, 털이 많은 세포
- 아미노산, 펩티드 및 단백질
- 단백질
- 황 화합물
- 유기 화학 물질
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 아미드
- 인돌
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 퓨린
- 뉴 클레오 시드
- 리보 뉴 클레오 시드
- 항체, 모노클로 날, 뮤린 유래
- 데 옥시 리보 뉴 클레오 시드
- 설폰 아미드
- 설폰
- 2- 클로로 데노 신
- 아데노신
- 퓨린 뉴 클레오 시드
- 데 옥시 아데노신
- 리툭시맙
- 베무라페닙
- 클라드리빈
- 오비누투 주맙
기타 연구 ID 번호
- 24-160
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .